Literature DB >> 18443431

EphA2 overexpression promotes ovarian cancer growth.

Chunhua Lu1, Mian M K Shahzad, Hua Wang, Charles N Landen, Seung W Kim, Julie Allen, Alpa M Nick, Nicholas Jennings, Michael S Kinch, Menashe Bar-Eli, Anil K Sood.   

Abstract

BACKGROUND: Silencing EphA2 has been shown to result in anti-tumor efficacy. However, it is not known whether increasing EphA2 expression specifically results in increased tumor growth and progression. We examined the effects of stable EphA2 transfection into poorly invasive ovarian cancer cells with regard to in vitro invasive and in vivo metastatic potential.
RESULTS: In low cell density, EphA2-overexpressing A2780 cells (A2780-EphA2) displayed less cell-cell contact, increased cell-extracellular matrix (ECM) attachment and anchorage-independent cell growth compared to empty vector controls. There was no significant effect on anchorage-dependent cell proliferation, migration or invasion. Increased expression of EphA2 promoted tumor growth and enhanced the metastatic potential in A2780-EphA2 human ovarian cancer xenografts. The overexpression of EphA2 resulted in enhanced microvessel density (MVD), but had no effect on tumor cell proliferation.
METHODS: EphA2 gene was introduced into A2780 cells by retroviral infection. The effects of increased EphA2 expression were examined on cellular morphology, and anchorage-dependent and independent cell growth. Furthermore, the effect of EphA2 overexpression on metastatic ability was determined using an orthotopic nude mouse model of ovarian carcinoma.
CONCLUSIONS: EphA2 promotes tumor growth by enhancing cell-ECM adhesion, increasing anchorage-independent growth and promoting angiogenesis.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18443431      PMCID: PMC2705979          DOI: 10.4161/cbt.7.7.6168

Source DB:  PubMed          Journal:  Cancer Biol Ther        ISSN: 1538-4047            Impact factor:   4.742


  46 in total

Review 1.  EphA2 as a target for ovarian cancer therapy.

Authors:  Charles N Landen; Michael S Kinch; Anil K Sood
Journal:  Expert Opin Ther Targets       Date:  2005-12       Impact factor: 6.902

2.  Overexpression of the EphA2 tyrosine kinase in prostate cancer.

Authors:  J Walker-Daniels; K Coffman; M Azimi; J S Rhim; D G Bostwick; P Snyder; B J Kerns; D J Waters; M S Kinch
Journal:  Prostate       Date:  1999-12-01       Impact factor: 4.104

3.  Interrelations between nuclear-factor kappa B activation, glial response and neuronal apoptosis in gerbil hippocampus after ischemia.

Authors:  K Domańska-Janik; A Bronisz-Kowalczyk; H Zajac; B Zabłocka
Journal:  Acta Neurobiol Exp (Wars)       Date:  2001       Impact factor: 1.579

4.  Soluble Eph A receptors inhibit tumor angiogenesis and progression in vivo.

Authors:  Dana M Brantley; Nikki Cheng; Erin J Thompson; Qing Lin; Rolf A Brekken; Philip E Thorpe; Rebecca S Muraoka; Douglas Pat Cerretti; Ambra Pozzi; Dowdy Jackson; Charles Lin; Jin Chen
Journal:  Oncogene       Date:  2002-10-10       Impact factor: 9.867

5.  Allele loss on chromosome 1p36 in epithelial ovarian cancers.

Authors:  A A Alvarez; A R Lambers; J M Lancaster; G L Maxwell; S Ali; C Gumbs; A Berchuck; P A Futreal
Journal:  Gynecol Oncol       Date:  2001-07       Impact factor: 5.482

6.  EphA2 overexpression causes tumorigenesis of mammary epithelial cells.

Authors:  D P Zelinski; N D Zantek; J C Stewart; A R Irizarry; M S Kinch
Journal:  Cancer Res       Date:  2001-03-01       Impact factor: 12.701

7.  Regulation of the EphA2 kinase by the low molecular weight tyrosine phosphatase induces transformation.

Authors:  Keith D Kikawa; Derika R Vidale; Robert L Van Etten; Michael S Kinch
Journal:  J Biol Chem       Date:  2002-08-06       Impact factor: 5.157

8.  Predicting the sites of metastases from lung cancer using molecular biologic markers.

Authors:  T A D'Amico; T A Aloia; M B Moore; D H Conlon; J E Herndon; M S Kinch; D H Harpole
Journal:  Ann Thorac Surg       Date:  2001-10       Impact factor: 4.330

9.  EphrinA1-induced cytoskeletal re-organization requires FAK and p130(cas).

Authors:  Nigel Carter; Tetsuya Nakamoto; Hisamaru Hirai; Tony Hunter
Journal:  Nat Cell Biol       Date:  2002-08       Impact factor: 28.824

10.  Synergistic therapy of human ovarian carcinoma implanted orthotopically in nude mice by optimal biological dose of pegylated interferon alpha combined with paclitaxel.

Authors:  Sean Tedjarati; Cheryl H Baker; Sachin Apte; Suyun Huang; Judith K Wolf; Jerald J Killion; Isaiah J Fidler
Journal:  Clin Cancer Res       Date:  2002-07       Impact factor: 12.531

View more
  36 in total

1.  Downregulation of EphA2 expression suppresses the growth and metastasis in squamous-cell carcinoma of the head and neck in vitro and in vivo.

Authors:  Yong Liu; Changyun Yu; Yuanzheng Qiu; Donghai Huang; Xiaojuan Zhou; Xin Zhang; Yongquan Tian
Journal:  J Cancer Res Clin Oncol       Date:  2011-11-16       Impact factor: 4.553

2.  EphA2 silencing in nasopharyngeal carcinoma leads to decreased proliferation, invasion and increased sensitization to paclitaxel.

Authors:  Pingqing Tan; Yong Liu; Changyun Yu; Zhongwu Su; Guo Li; Xiaojuan Zhou; Donghai Huang; Xin Zhang; Yuanzheng Qiu; Yongquan Tian
Journal:  Oncol Lett       Date:  2012-06-08       Impact factor: 2.967

3.  Therapeutic synergy between microRNA and siRNA in ovarian cancer treatment.

Authors:  Masato Nishimura; Eun-Jung Jung; Maitri Y Shah; Chunhua Lu; Riccardo Spizzo; Masayoshi Shimizu; Hee Dong Han; Cristina Ivan; Simona Rossi; Xinna Zhang; Milena S Nicoloso; Sherry Y Wu; Maria Ines Almeida; Justin Bottsford-Miller; Chad V Pecot; Behrouz Zand; Koji Matsuo; Mian M Shahzad; Nicholas B Jennings; Cristian Rodriguez-Aguayo; Gabriel Lopez-Berestein; Anil K Sood; George A Calin
Journal:  Cancer Discov       Date:  2013-09-03       Impact factor: 39.397

4.  Hsp90 is an essential regulator of EphA2 receptor stability and signaling: implications for cancer cell migration and metastasis.

Authors:  Balasubramaniam Annamalai; Xueguang Liu; Udhayakumar Gopal; Jennifer S Isaacs
Journal:  Mol Cancer Res       Date:  2009-06-30       Impact factor: 5.852

5.  Truncation of histone H2A's C-terminal tail, as is typical for Ni(II)-assisted specific peptide bond hydrolysis, has gene expression altering effects.

Authors:  Aldona A Karaczyn; Robert Y S Cheng; Gregory S Buzard; James Hartley; Dominic Esposito; Kazimierz S Kasprzak
Journal:  Ann Clin Lab Sci       Date:  2009       Impact factor: 1.256

6.  MicroRNA 520d-3p inhibits gastric cancer cell proliferation, migration, and invasion by downregulating EphA2 expression.

Authors:  Ruixin Li; Weijie Yuan; Wenjuan Mei; Keda Yang; Zihua Chen
Journal:  Mol Cell Biochem       Date:  2014-07-26       Impact factor: 3.396

7.  Expression profiling of the ovarian surface kinome reveals candidate genes for early neoplastic changes.

Authors:  Tanja Pejovic; Nupur T Pande; Motomi Mori; Paulette Mhawech-Fauceglia; Christina Harrington; Solange Mongoue-Tchokote; Daniel Dim; Christopher Andrews; Amy Beck; Yukie Tarumi; Jovana Djilas; Fabio Cappuccini; Otavia Caballero; Jiaqi Huang; Samuel Levy; Alexia Tsiamouri; Joanna Cain; Grover C Bagby; Robert L Strausberg; Andrew J Simpson; Kunle O Odunsi
Journal:  Transl Oncol       Date:  2009-12       Impact factor: 4.243

8.  Eph receptors and ephrin ligands: important players in angiogenesis and tumor angiogenesis.

Authors:  Birgit Mosch; Bettina Reissenweber; Christin Neuber; Jens Pietzsch
Journal:  J Oncol       Date:  2010-03-10       Impact factor: 4.375

9.  One-Bead-Two-Compound Thioether Bridged Macrocyclic γ-AApeptide Screening Library against EphA2.

Authors:  Yan Shi; Sridevi Challa; Peng Sang; Fengyu She; Chunpu Li; Geoffrey M Gray; Alekhya Nimmagadda; Peng Teng; Timothy Odom; Yan Wang; Arjan van der Vaart; Qi Li; Jianfeng Cai
Journal:  J Med Chem       Date:  2017-11-14       Impact factor: 7.446

10.  Expression of EphA2 and E-cadherin in gastric cancer: correlated with tumor progression and lymphogenous metastasis.

Authors:  Weijie Yuan; Zhikang Chen; Shaobin Wu; Jie Ge; Shi Chang; Xianwei Wang; Jingxiang Chen; Zihua Chen
Journal:  Pathol Oncol Res       Date:  2009-09       Impact factor: 3.201

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.